Cefiderocol for Extensively Drug-Resistant Gram-Negative Bacterial Infections: Real-world Experience From a Case Series and Review of the Literature.
Sandra ZinggG Jacopo NicolettiSabine KusterMilena JunkerAndreas WidmerAdrian EgliVladimira HinicParham SendiManuel BattegayVeronika BättigNina KhannaSarah Tschudin-SutterPublished in: Open forum infectious diseases (2020)
Cefiderocol is a new siderophore cephalosporin with activity against carbapenem-resistant gram-negative bacteria. Data on its clinical efficacy are limited to complicated urinary tract infections. We present a series of 3 patients successfully treated with cefiderocol for complicated health care-associated infections and review published case reports.
Keyphrases
- gram negative
- multidrug resistant
- drug resistant
- acinetobacter baumannii
- urinary tract infection
- healthcare
- end stage renal disease
- ejection fraction
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- electronic health record
- randomized controlled trial
- systematic review
- machine learning
- patient reported
- health information